ABSTRACT
Background Truncating variants in desmoplakin (DSPtv) are an important cause of arrhythmogenic cardiomyopathy (ACM), however the genetic architecture and genotype-specific risk factors are incompletely understood. We evaluated phenotype, risk factors for ventricular arrhythmias, and underlying genetics of DSPtv cardiomyopathy.
Methods Individuals with DSPtv and any cardiac phenotype, and their gene-positive family members were included from multiple international centers. Clinical data and family history information were collected. Event-free survival from ventricular arrhythmia was assessed. Variant location was compared between cases and controls, and literature review of reported DSPtv performed.
Results There were 98 probands and 72 family members (mean age at diagnosis 43 ± 18 years, 59% female) with a DSPtv, of which 146 were considered clinically affected. Ventricular arrhythmia (sudden cardiac arrest, sustained ventricular tachycardia, appropriate implantable cardioverter defibrillator therapy) occurred in 56 (33%) individuals. DSPtv location and proband status were independent risk factors for ventricular arrhythmia, while prior risk factors showed no association. Further, gene region was important with variants in cases (cohort n=98, Clinvar n=168) more likely to occur in the regions resulting in nonsense mediated decay of both major DSP isoforms, compared to n=124 gnomAD control variants (148 [83.6%] versus 29 [16.4%], p<0.0001).
Conclusions In the largest series of individuals with DSPtv, we demonstrate variant location is a novel risk factor for ventricular arrhythmia, can inform variant interpretation, and provide critical insights to allow precision-based clinical management.
Competing Interest Statement
J Ingles receives research grant support from Myokardia, Inc. J Ware reports research grant support and consultancy fees from Myokardia, Inc, unrelated to this study. C Reuter is a consultant for My Gene Counsel. M Wheeler is a stockholder of Personalis Inc. The remaining authors have nothing to disclose.
Funding Statement
C Burns is the recipient of an Australia Postgraduate Award (APA). RD Bagnall is supported by a grant from New South Wales Health. C Semsarian is the recipient of a National Health and Medical Research Council (NHMRC) Practitioner Fellowship (#1154992). J Ware is supported by the Wellcome Trust, the Medical Research Council (UK), the British Heart Foundation, the NIHR Royal Brompton Biomedical Research Unit, and the NIHR Imperial College Biomedical Research Centre. JP van Tintelen, A Wilde, P Volders, MP van den Berg and ET Hoorntje acknowledge the support from the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation (2014-40 DOSIS; 2012-10 PREDICT; 2018-30 PREDICT2; 2015-12 eDETECT). J Ingles is the recipient of an NHMRC Career Development Fellowship (#1162929).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional ethics approval was granted by individual sites; including Sydney Local Health District, Royal Prince Alfred Hospital, Australia; Royal Brompton & Harefield Hospitals Cardiovascular Biobank (National Research Ethics Service), UK. Waiver of consent was granted at Stanford School of Medicine Internal Review Board, USA. All individual-level data were de-identified.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
FUNDING C Burns is the recipient of an Australia Postgraduate Award (APA). RD Bagnall is supported by a grant from New South Wales Health. C Semsarian is the recipient of a National Health and Medical Research Council (NHMRC) Practitioner Fellowship (#1154992). J Ware is supported by the Wellcome Trust, the Medical Research Council (UK), the British Heart Foundation, the NIHR Royal Brompton Biomedical Research Unit, and the NIHR Imperial College Biomedical Research Centre. JP van Tintelen, A Wilde, P Volders, MP van den Berg and ET Hoorntje acknowledge the support from the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation (2014-40 DOSIS; 2012-10 PREDICT; 2018-30 PREDICT2; 2015-12 eDETECT). J Ingles is the recipient of an NHMRC Career Development Fellowship (#1162929).
CONFLICT OF INTEREST NOTIFICATION J Ingles receives research grant support from Myokardia, Inc, unrelated to this study. J Ware reports research grant support and consultancy fees from Myokardia, Inc, unrelated to this study. C Reuter is a consultant for My Gene Counsel. M Wheeler is a stockholder of Personalis Inc. The remaining authors have nothing to disclose.
ETHICS DECLARATION Institutional ethics approval was granted by individual sites; including Sydney Local Health District, Royal Prince Alfred Hospital, Australia; Royal Brompton & Harefield Hospitals Cardiovascular Biobank (National Research Ethics Service), UK. Waiver of consent was granted at Stanford School of Medicine Internal Review Board, USA. All individual-level data were de-identified.
AUTHOR INFORMATION 1. Conceptualization: CB, EJH, JW, JPvT, JI; 2. Data curation: ALL; 3. Formal Analysis: EJH, CB, JI; 4. Funding acquisition: JPvT, JI; 5. Investigation: EJH, CB, BC, VP, JW, PvT, JI; 6. Methodology: ALL; 6. Project administration: JI; 7. Resources: JW, PT, JI; 8. Software: Not Applicable; 9: Supervision: JW, PvT, JI; 10. Validation: Not Applicable; 11. Visualization: JI; 12. Writing – original draft: EJH, CB, JI; 13. Writing – review & editing: ALL.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos